middle.news
Nexsen pauses StrepSure to sharpen FDA pathway as device contract announcement nears
10:21am on Thursday 24th of September, 2026 AEST
•
Healthcare Technology
Read Story
Nexsen pauses StrepSure to sharpen FDA pathway as device contract announcement nears
10:21am on Thursday 24th of September, 2026 AEST
Key Points
StrepSure FDA submission delayed by approximately one quarter
Interim review prompts targeted performance enhancements
Clinical enrolment suspended with no adverse safety signal reported
Shares suspended pending potentially material device contract announcement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexsen (ASX:NXN)
OPEN ARTICLE